Dr Kola Tytler MBBS CertHE MBA MRCGPClinical Lead • iatroX
For patients diagnosed with chronic myeloid leukaemia (CML) in the chronic phase, the recommended first-line treatments primarily involve tyrosine kinase inhibitors (TKIs) NICE NG35. These agents are considered the standard of care for initial therapy García-Gutiérrez et al. 2022. Specific TKIs commonly used as first-line options include imatinib, nilotinib, dasatinib, and bosutinib García-Gutiérrez et al. 2022. The choice among these TKIs may depend on various factors, including patient characteristics and physician preference Deininger et al. 2020García-Gutiérrez et al. 2022. For children and adolescents with CML in the chronic phase, TKI therapy is also the recommended approach Millot et al. 2025.
Key References
- NG35 - Myeloma: diagnosis and management
- NG52 - Non-Hodgkin's lymphoma: diagnosis and management
- CKS - Multiple myeloma
- CKS - Erythrocytosis/polycythaemia
- CKS - Polycythaemia/erythrocytosis
- (Deininger et al., 2020): Chronic Myeloid Leukemia, Version 2.2021, NCCN Clinical Practice Guidelines in Oncology.
- (García-Gutiérrez et al., 2022): A clinician perspective on the treatment of chronic myeloid leukemia in the chronic phase.
- (Millot et al., 2025): Management of children and adolescents with chronic myeloid leukemia in chronic phase: International pediatric chronic myeloid leukemia expert panel recommendations.